Lee · Oncogene 2011 · narrative review · n=?

Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients.

Cited 309 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Narrative review of mechanistic, preclinical, and preliminary clinical studies.

PubMed 21516129 · doi:10.1038/onc.2011.91 · record verified 2026-08-30

What was done

This is a narrative review comparing the cellular protective mechanisms and therapeutic potential of acute fasting (zero caloric intake) versus long-term dietary restriction (20% to 40% caloric reduction) across simple model organisms, rodents, and preliminary human clinical reports in the context of cancer chemotherapy.

What was found

In mammals, fasting causes an over 50% reduction in circulating glucose and insulin-like growth factor 1 (IGF-1) levels, triggering protective signaling pathways (differential stress resistance) that oncogene-bearing cancer cells fail to activate. Preliminary clinical reports note that fasting for up to 5 days followed by normal feeding may protect human patients against chemotherapy toxicity without causing chronic weight loss. By contrast, chronic dietary restriction requires weeks to months to take effect, induces more modest glucose and IGF-1 reductions, and leads to sustained weight loss in both rodents and humans. Quantitative human trial data were not detailed in the abstract.

Why it matters

It highlights short-term fasting as a distinct, actionable metabolic strategy to enhance chemotherapy tolerability and differential cellular protection without the chronic wasting associated with long-term caloric restriction.

Limits

This is a narrative review rather than a systematic review or meta-analysis. The human findings mentioned are preliminary, and the abstract lacks quantitative clinical efficacy data, safety metrics, patient characteristics, and sample sizes.

Cited by